CD8A and melanoma: The observed increase in IL-2 levels among melanoma patients treated with Nivolumab is likely attributable to activation and expansion of CD4+ helper T cells and CD8+ cytotoxic T lymphocytes, which are principal producers of IL-2 following T-cell receptor engagement.